So far, the focus of interest in MDM2 overexpression has been on drug-resistant childhood ALL cases, whereas its potential relevance in E/R-positive cases has been largely disregarded because of the comparably favorable outcome of these leukemias. This evidence concerns the gene MDM2 and leukemia.